Global pharma major Lupin Limited (Lupin) has received tentative approval from the United States Food and Drug Administration (USFDA) under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine and Tenofovir Alafenamide (DETAF) tablets.

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries. This product would be manufactured at Lupin’s Nagpur facility in India.

Commenting on the same, Naresh Gupta, President - API and Global Institution Business, Lupin said, “We are committed to providing affordable and quality treatment options to patients in low- and middle- income countries. We are pleased that the USFDA has tentatively approved DETAF, which will significantly enhance our HIV portfolio.”

Lupin, an innovation-led transnational pharmaceutical company, develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the US by prescription. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.